Abstract:Abstract There is substantial interest in the potential for traumatic brain injury to result in progressive neurological deterioration. While blood biomarkers such as glial fibrillary acid protein and neurofilament light have been widely explored in characterising acute traumatic brain injury, their use in the chronic phase is limited. Given increasing evidence that these proteins may be markers of ongoing neurodegeneration in a range of diseases, we examined their relationship to imaging changes and functional outcome in the months to years following traumatic brain injury. Two-hundred and three patients were recruited in two separate cohorts; six months post-injury (n=165); and >5 years post-injury (n=38; 12 of whom also provided data ∼8 months post-TBI). Subjects underwent blood biomarker sampling (n=199) and magnetic resonance imaging (n=172; including diffusion tensor imaging). Data from patient cohorts were compared to 59 healthy volunteers and 21 non-brain injury trauma controls. Mean diffusivity and fractional anisotropy were calculated in cortical grey matter, deep grey matter and whole brain white matter. Accelerated brain ageing was calculated at a whole brain level as the predicted age difference defined using T1-weighted images, and at a voxel-based level as the annualised Jacobian determinants in white matter and grey matter, referenced to a population of 652 healthy control subjects. Serum neurofilament light concentrations were elevated in the early chronic phase. While GFAP values were within the normal range at ∼8 months, many patients showed a secondary and temporally distinct elevations up to >5 years after injury. Biomarker elevation at six months was significantly related to metrics of microstructural injury on diffusion tensor imaging. Biomarker levels at ∼8 months predicted white matter volume loss at >5 years, and annualised brain volume loss between ∼8 months and 5 years. Patients who worsened functionally between ∼8 months and >5 years showed higher than predicted brain age and elevated neurofilament light levels. Glial fibrillary acid protein and neurofilament light levels can remain elevated months to years after traumatic brain injury, and show distinct temporal profiles. These elevations correlate closely with microstructural injury in both grey and white matter on contemporaneous quantitative diffusion tensor imaging. Neurofilament light elevations at ∼8 months may predict ongoing white matter and brain volume loss over >5 years of follow up. If confirmed, these findings suggest that blood biomarker levels at late time points could be used to identify traumatic brain injury survivors who are at high risk of progressive neurological damage.

Blood‐based biomarkers and traumatic brain injury—A clinical perspective

Biofluid biomarkers of traumatic brain injury

The Known Unknowns: An Overview of the State of Blood-Based Protein Biomarkers of Mild Traumatic Brain Injury

Blood Biomarkers for the Management of Mild Traumatic Brain Injury in Clinical Practice

Blood biomarkers for mild traumatic brain injury: a selective review of unresolved issues

Biomarkers in the Clinical Diagnosis and Management of Traumatic Brain Injury

Association between Blood and Computed Tomographic Imaging Biomarkers in a Cohort of Mild Traumatic Brain Injury Patients

Comparing Blood Biomarkers to Clinical Decision Rules to Select Patients Suspected of Traumatic Brain Injury for Head Computed Tomography.

Blood biomarkers on admission in acute traumatic brain injury: Relations to severity, CT findings and care path in the CENTER-TBI study

Post-acute blood biomarkers and disease progression in traumatic brain injury

Biomarkers in Acute Traumatic Brain Injury: A Systematic Review and Meta-Analysis

Serum Protein Biomarkers in the Management of Severe Traumatic Brain Injury

Biomarkers in traumatic brain injury: new concepts

Serum Biomarkers and Disease Progression in CT-negative Mild Traumatic Brain Injury.

Candidate Molecular Biomarkers of Traumatic Brain Injury: A Systematic Review

Biomarkers and New Pharmacological Targets

Blood-Based Biomarkers in Traumatic Brain Injury: A Narrative Review With Implications for the Legal System

Blood biomarkers: a new solution to the silent pandemic of traumatic brain injury

Fluid biomarkers of chronic traumatic brain injury

Examining four blood biomarkers for the detection of acute intracranial abnormalities following mild traumatic brain injury in older adults

Predictive Biomarkers of Recovery in Traumatic Brain Injury